NVDA, ORCL among premarket gainers

Jignesh Mehta2020-09-14

Immunomedics (NASDAQ:IMMU) +106% after Gilead to buy the company for $21B (~$88/share). Cassava Sciences (NASDAQ:SAVA) +94% on positive data on lead drug in Alzheimer's. China Natural Resources (...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

凡正奎
2020-09-15
凡正奎
说说你对这篇新闻的看法...

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2067843107?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2020-09-14 20:39","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2067843107","market":"us","top_or_hot":-1,"title":"NVDA, ORCL among premarket gainers","media":"Jignesh Mehta","content":"<div>\n<p>Immunomedics (NASDAQ:IMMU) +106% after Gilead to buy the company for $21B (~$88/share).\nCassava Sciences (NASDAQ:SAVA) +94% on positive data on lead drug in Alzheimer's.\nChina Natural Resources (...</p>\n\n<a href=\"https://seekingalpha.com/news/3613613-nvda-orcl-among-premarket-gainers\">网页链接</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NVDA, ORCL among premarket gainers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNVDA, ORCL among premarket gainers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2020-09-14 20:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3613613-nvda-orcl-among-premarket-gainers><strong>Jignesh Mehta</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Immunomedics (NASDAQ:IMMU) +106% after Gilead to buy the company for $21B (~$88/share).\nCassava Sciences (NASDAQ:SAVA) +94% on positive data on lead drug in Alzheimer's.\nChina Natural Resources (...</p>\n\n<a href=\"https://seekingalpha.com/news/3613613-nvda-orcl-among-premarket-gainers\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DVAX","symbol_name":"德纳维制药","start_time":0,"source_url":"https://seekingalpha.com/news/3613613-nvda-orcl-among-premarket-gainers","article_id":"2067843107","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2067843107","pubTimestamp":1600087144,"columns":[],"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Immunomedics (NASDAQ:IMMU) +106% after Gilead to buy the company for $21B (~$88/share).\nCassava Scie","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"DVAX":"德纳维制药","CHNR":"中国天然资源","IMMU":"Immunomedics","VIR":"Vir Biotechnology, Inc.","TRVN":"Trevena, Inc.","FSLY":"Fastly, Inc.","ORCL":"甲骨文","SGEN":"Seagen","LODE":"Comstock Mining","SPAQ":"HORIZON KINETICS SPAC ACTIVE ETF","VXRT":"Vaxart, Inc","EVGN":"Evogene Ltd.","MRSN":"Mersana Therapeutics Inc.","ETON":"Eton Pharmaceuticals, Inc.","MRNS":"Marinus Pharmaceuticals","SRNE":"索伦托医疗","SAVA":"Cassava Sciences Inc","GME":"游戏驿站","IFRX":"InflaRx N.V.","NVDA":"英伟达"},"translate_title":"盘前涨幅居前的NVDA，ORCL","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNS":0.9,"VXRT":0.9,"VIR":0.9,"TRVN":0.9,"SRNE":0.9,"SPAQ":0.9,"SGMS":0.9,"SGEN":0.9,"SAVA":0.9,"OSTK":0.9,"ORCL":0.9,"NVDA":0.9,"MRSN":0.9,"ATIF":0.9,"LODE":0.9,"IMMU":0.9,"IFRX":0.9,"HMI":0.9,"GME":0.9,"FSLY":0.9,"EVGN":0.9,"ETON":0.9,"DVAX":0.9,"DPHC":0.9,"CHNR":0.9},"content_text":"Immunomedics (NASDAQ:IMMU) +106% after Gilead to buy the company for $21B (~$88/share).\nCassava Sciences (NASDAQ:SAVA) +94% on positive data on lead drug in Alzheimer's.\nChina Natural Resources (NASDAQ:CHNR) +30% on interim results.\nScientific Games Corporation (NASDAQ:SGMS) +25% as institutional investors, including Caledonia to acquire stake from MacAndrews & Forbes for $28.00/share.\nVaxart (NASDAQ:VXRT) +16% on FDA clearance of oral covid vaccine.\nATIF Holdings Limited (NASDAQ:ATIF) +15% after signing strategic cooperation for IPOEX.\nComstock Mining (NYSEMKT:LODE) +14% on completing Lucerne Transaction.\nMersana Therapeutics (NASDAQ:MRSN) +14%.\nEvogene (NASDAQ:EVGN) +13%.\nGameStop (NYSE:GME) +11% after upgraded to buy from hold at Jefferies.\nDynavax Technologies (NASDAQ:DVAX) +11% after vaccine supply deal with Valneva.\nMarinus Pharmaceuticals (NASDAQ:MRNS) +18% after entering into a five-year development contract with the BARDA.\nInflaRx N.V. (NASDAQ:IFRX) +10% after launching late-stage study of IFX-1 in COVID-19 induced pneumonia.\nDiamondPeak Holdings (NASDAQ:DPHC) +10%.\nHuami Corporation (NYSE:HMI) +9%.\nVir Biotechnology (NASDAQ:VIR) +10%.\nSpartan Energy Acquisition (NYSE:SPAQ) +9%.\nSeattle Genetics (NASDAQ:SGEN) +9% after two new strategic oncology collaborations.\nSorrento Therapeutics (NASDAQ:SRNE) +9% on agreement with Mayo Clinic securing exclusive rights to a technology platform.\nOracle Corporation (NYSE:ORCL) +8% as company has been chosen to acquire TikTok U.S. as tech partner.\nTrevena (NASDAQ:TRVN) +7%.\nEton Pharmaceuticals (NASDAQ:ETON) +6%.\nOverstock.com (NASDAQ:OSTK) +6%.\nFastly (NYSE:FSLY) +6%.\nNVIDIA Corporation (NASDAQ:NVDA) +6% on $40B deal for acquisition of Arm Ltd from SoftBank.  See all stocks on the move »Now read: Fastly And The TikTok Drama: Be Greedy When Others Are Fearful »","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":972364147,"gmtCreate":1600101177789,"gmtModify":1703820363415,"author":{"id":"3549426554049014","authorId":"3549426554049014","name":"凡正奎","avatar":"https://static.tigerbbs.com/f4aed5171f7ad1bdaa306218ad94a2cc","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3549426554049014","authorIdStr":"3549426554049014"},"htmlText":"说说你对这篇新闻的看法...","listText":"说说你对这篇新闻的看法...","text":"说说你对这篇新闻的看法...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/972364147","repostId":2067843107,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":0,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2067843107"}